Edgewise Therapeutics, Inc.

This study tests an experimental drug called sevasemten in 76 children aged 4-9 with Duchenne muscular dystrophy. The goal is to see if the drug is safe and can help control the disease by measuring side effects, drug levels in the blood, and muscle health markers. Participants a…

This study tests an experimental drug called EDG-5506 (sevasemten) in 43 children aged 6 to 17 with Duchenne muscular dystrophy who have already received gene therapy. The goal is to see if the drug is safe and how it affects muscle health markers. Participants are randomly assig…

This study looks at the long-term safety and effects of a drug called EDG-5506 (sevasemten) in adults and teenagers with Becker muscular dystrophy, a muscle-weakening disease. About 260 people who have already been in earlier EDG-5506 studies will take the drug and be monitored f…

This study tests a new medicine called EDG-7500 in 100 adults with hypertrophic cardiomyopathy, a condition where the heart muscle is abnormally thick. The goal is to see if the drug is safe and can reduce blockage of blood flow from the heart. Participants will receive either a …

This study tests an experimental drug called sevasemten (EDG-5506) in 244 adults and adolescents with Becker muscular dystrophy, a genetic condition that causes progressive muscle weakness. Participants receive either the drug or a placebo to see if it is safe and can improve mus…